信保人寿

Assurant Inc earns a 2-star quantitative star rating, reflecting our opinion that this share class is a somewhat unattractive choice, and investors should look elsewhere for more fruitful opportunities. The stock currently trades at a 3% premium over our quantitative fair value estimate of $258.23 per share; however, this estimate should be taken with a pinch of salt due to its medium uncertainty rating. We require the price/fair value ratio to move a certain amount before the star rating can change. This stability-enhancing buffer is in effect for this stock.

The company's balance sheet weakens our estimated valuation. Low leverage can limit a company's ability to invest in growth, potentially reducing shareholder value compared with a balanced use of debt and equity financing. For example, the firm's EBITDA/interest coverage ratio of 15.1 sits in the top 50% compared with peers globally. The company may have too conservative of a balance sheet based on its high EBITDA/interest coverage ratio, potentially underinvesting in growth opportunities and undermining the long-term trajectory of cash flows. We believe this is a sign that shares could be overvalued.

Conversely, the company's profitability is reassuring. Highly profitable companies are often more resilient in recessions and are likely to generate stronger future cash flows for shareholders. The firm's earnings yield of 9.1%, a core component of profitability, lies in the top 30% compared with peers globally. This suggests that it is generating substantial earnings relative to its share price, which, despite our unfavorable price/fair value ratio, is a positive attribute.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance may signify a bull trap, in light of other detractors from our model.

With its quantitative economic moat rating of none, this business is unlikely to consistently outearn its cost of capital without structural protection from competition. However, its financial health score is strong, suggesting that the company should be well positioned to weather tough times.